BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38717372)

  • 1. Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment.
    Caldarola G; Pinto LM; Bellinato F; Bernardini N; Campione E; Chiricozzi A; Colonna L; De Simone C; Diluvio L; Gisondi P; Matteini E; Tomassetti E; Tolino E; Bianchi L; Peris K
    Expert Opin Drug Saf; 2024 May; ():1-5. PubMed ID: 38717372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
    Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
    Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
    Wei D; Chen Y; Shen Y; Xie B; Song X
    Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.
    Kołcz K; Żychowska M; Sawińska E; Reich A
    Dermatol Ther (Heidelb); 2023 Mar; 13(3):843-856. PubMed ID: 36639612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for the treatment of alopecia areata.
    Ramírez-Marín HA; Tosti A
    Expert Opin Emerg Drugs; 2022 Dec; 27(4):379-387. PubMed ID: 36408593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
    De Greef A; Thirion R; Ghislain PD; Baeck M
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2869-2877. PubMed ID: 37717224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase inhibitors for alopecia areata.
    King BA; Craiglow BG
    J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
    Lensing M; Jabbari A
    Front Immunol; 2022; 13():955035. PubMed ID: 36110853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
    Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
    J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
    Stefanis AJ
    Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib for the Treatment of Alopecia Areata.
    Freitas E; Guttman-Yassky E; Torres T
    Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatments for alopecia areata: a network meta-analysis.
    Mateos-Haro M; Novoa-Candia M; Sánchez Vanegas G; Correa-Pérez A; Gaetano Gil A; Fernández-García S; Ortega-Quijano D; Urueña Rodriguez MG; Saceda-Corralo D; Bennouna-Dalero T; Giraldo L; Tomlinson J; Vaño-Galván S; Zamora J
    Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013719. PubMed ID: 37870096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study.
    Huang J; Tan Z; Tang Y; Shi W
    Front Med (Lausanne); 2023; 10():1287139. PubMed ID: 37920596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
    Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib: A Review in Severe Alopecia Areata.
    Fung S; Shirley M
    Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for alopecia areata: JAK inhibitors.
    Iorizzo M; Tosti A
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):77-81. PubMed ID: 29466675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
    Dillon KL
    Clin Cosmet Investig Dermatol; 2021; 14():691-714. PubMed ID: 34211288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
    Ramot Y; Zlotogorski A
    Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.